The Cutting Edge of Medical Technology Content, Community & Collaboration
Time: January 19, 2018 from 10am to 11:15am
Location: Fremont
Street: 161 Mission Falls Lane, Suite 216,
City/Town: Fremont
Website or Map: http://www.compliance4all.com…
Phone: 18004479407
Event Type: online
Organized By: Event Manager
Latest Activity: Dec 1, 2017
Overview:
How it may be integrated with the recommendations of the guidance documents on CMC requirements.
Areas Covered in the Session:
Discussion of the elements found in the guidance document for Phase 1 material
What to do at really early stages
What about special IND studies?
What about preclinical studies?
Who Will Benefit:
Regulatory Affairs personnel who coordinate activities for the CMC sections of submissions
QA/QC personnel who need to plan work on early stage material
R & D personnel who will contribute data to CMC sections
Project managers for product development studies
Quality systems auditors
Consultants
Speaker Profile:
Steven S. Kuwahara , Ph.D. is the founder and Principal of GXP BioTechnology LLC, a consulting firm that works in the areas covered by the GLP and GMP of drugs, biologics, and nutraceuticals. Steve has over 30 years of experience in supervising quality control laboratories, including an animal testing facility, and in performing GLP and GMP audits of internal and external testing laboratories .
Event Fee: One Dial-in One Attendee Price: US$150.00
Contact Detail:
Compliance4All DBA NetZealous,
Phone: +1-800-447-9407
Email: support@compliance4All.com
© 2024 Created by CC-Conrad Clyburn-MedForeSight. Powered by
RSVP for Products Used in Early Phase IND Studies to add comments!
Join MedTech I.Q.